Headlines

Why high risk women are reluctant to take breast cancer drug

 2 weeks ago       21 Views

Only about a fifth of women at higher risk of developing breast cancer think they need to take a drug proven to help prevent the disease, according to new research.

Some 72% said they were worried about the long-term effects of tamoxifen, while 57% thought the drug would give them unpleasant side-effects.

The researchers, led by a team from the University of Leeds, asked more than 400 healthy women at a higher risk of breast cancer, from 20 clinics across England, whether they thought they needed to take tamoxifen, as well as their concerns about medication.

Just under a quarter (24%) of the women thought people on medication should take regular breaks from the drugs; 23% said they were very sensitive to medicines and 17% believed natural remedies were safer than medicines.

Women who believed the medication was less necessary and had more concerns about its use were less likely to be taking tamoxifen at follow-up.

“There are some potential side effects with tamoxifen, and other medications that can help prevent cancer, but it’s vital that they have all the information, so they can make the best choice for them.” Dr Julie Sharp, Cancer Research UK The study was funded by Cancer Research UK and published in the journal Clinical Breast Cancer.

“We need to make sure health care professionals are adequately equipped to discuss the potential benefits and harms of preventive treatment with their patients so that women are well informed before deciding whether or not to take a drug.” Dr Julie Sharp, Cancer Research UK’s head of health information, said: “It’s understandable that women considering taking a new medicine might have some concerns and that, for some, it won’t be the right option.


Author: @DailyCupofYoga

Source: leeds.ac.uk

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.